Mdma: Research Areas Needing More Emphasis

The summary for the Mdma: Research Areas Needing More Emphasis grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Mdma: Research Areas Needing More Emphasis: The purpose of this PA is to provide an optimally comprehensive, strategic, and balanced MDMA (3,4-methylenedioxymethamphetamine) research program, given the upsurge in MDMA abuse worldwide, including its abuse outside the rave scene. Although researchers have made great strides in characterizing MDMAs neural mechanisms and neurotoxicity, it is necessary now to focus on specific areas of MDMA research, across all research disciplines, urgently needing our attention. For the purpose of this PA, the term MDMA is defined as 3,4-methylenedioxymethamphetamine and its very close structural analogues, such as p-methoxyamphetamine (PMA), p-methoxymethamphetamine (PMMA), and 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA), insofar as they share specific subjective, discriminative stimulus, or toxicological properties with 3,4-methylenedioxymethamphetamine; however, methamphetamine and other amphetamines that are characterized by neurotoxic effects on central dopaminergic systems in experimental animals are not included in this definition. Ecstasy is defined as a preparation (usually a tablet) supposed by its users to contain MDMA.

Federal Grant Title:	Mdma: Research Areas Needing More Emphasis
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health Education
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PA-04-152
Type of Funding:	Grant
CFDA Numbers:	93.279
CFDA Descriptions:	Drug Abuse Research Programs
Current Application Deadline:	No deadline provided
Original Application Deadline:	Multiple Receipt Dates - See Link to Full Announce
Posted Date:	Sep 08, 2004
Creation Date:	Dec 07, 2006
Archive Date:	Feb 03, 2007
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Small businesses Public housing authorities/Indian housing authorities Public and State controlled institutions of higher education City or township governments For profit organizations other than small businesses Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Others (see text field entitled "Additional Information on Eligibility" for clarification) County governments Native American tribal organizations (other than Federally recognized tribal governments) State governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) Independent school districts
Additional Information on Eligibility: Eligible agencies of the Federal Government are eligible to apply. Foreign institutions are eligible to apply.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [email protected] NIH OER Webmaster
Similar Government Grants: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical ...; • Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...; • Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Tr...; • Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial option...; • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards; • Drug Abuse Aspects of Hiv/Aids and Other Infections; • Epidemiology of Drug Abuse
More Grants from the National Institutes of Health: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...; • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...